Novavax NVAX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$87.84M-120% | $440.3M+28.8% | $341.75M-19.2% | $422.82M-11.7% | $478.7M+355% | ||
| $22.34M-19.1% | $27.61M-21.1% | $35.01M-14.9% | $41.12M-8.0% | $44.69M-7.9% | ||
| $33.45M-7.1% | $36.02M-6.4% | $38.5M-8.3% | $42M-10.4% | $46.88M-2.6% | ||
| —— | —— | —— | -$630.94M-233% | -$189.21M-117% | ||
| $5.36M-5.7% | $5.69M+2.6% | $5.54M+13.2% | $4.9M-37.0% | $7.77M-40.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$59.93M+80.3% | -$303.62M+5.0% | -$319.61M+25.1% | -$426.58M-96.2% | -$217.46M-465% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Novavax generate?
- Novavax (NVAX) generated -$384.9M in operating cash flow over the trailing twelve months.
- What is Novavax's free cash flow?
- After $5.4M of capital expenditures, Novavax's free cash flow was -$389.7M over the trailing twelve months, down 288.4% year over year.
- Where does Novavax's cash flow data come from?
- Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
